The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …

Background Epidermal growth factor receptor (EGFR) genotype is crucial for treatment
decision making in lung cancer, but it can be affected by tumour heterogeneity and invasive …

Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …

Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …

Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …